Short Interest in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Expands By 40.8%

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totaling 335 shares, a growth of 40.8% from the December 31st total of 238 shares. Based on an average daily volume of 7,116 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are sold short. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 7,116 shares, the short-interest ratio is presently 0.0 days.

Alterity Therapeutics Stock Performance

Shares of Alterity Therapeutics stock opened at $3.17 on Friday. Alterity Therapeutics has a 1 year low of $2.52 and a 1 year high of $7.00. The business has a 50 day moving average price of $3.30 and a 200 day moving average price of $4.17.

Hedge Funds Weigh In On Alterity Therapeutics

Several institutional investors have recently added to or reduced their stakes in ATHE. Greenleaf Trust acquired a new stake in Alterity Therapeutics in the 2nd quarter worth about $70,000. Citadel Advisors LLC purchased a new position in shares of Alterity Therapeutics during the 3rd quarter worth about $83,000. HB Wealth Management LLC acquired a new stake in shares of Alterity Therapeutics in the third quarter worth approximately $220,000. Finally, Twin Lakes Capital Management LLC grew its holdings in Alterity Therapeutics by 2,250.3% in the third quarter. Twin Lakes Capital Management LLC now owns 139,258 shares of the company’s stock valued at $524,000 after purchasing an additional 133,333 shares during the period. 2.14% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have issued reports on ATHE. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alterity Therapeutics in a report on Wednesday, January 21st. Canaccord Genuity Group initiated coverage on Alterity Therapeutics in a report on Wednesday, December 17th. They issued a “speculative buy” rating on the stock. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Alterity Therapeutics currently has an average rating of “Hold”.

Alterity Therapeutics Company Profile

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.